Biotech | January 22, 2022
Positive top-line results for bimekizumab in second phase 3 psoriatic arthritis study
UCB plans to submit regulatory applications in Q3 2022
UCB plans to submit regulatory applications in Q3 2022
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Ram’s appointment follows the launch of the CDI India division in October 2021.
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
Unlike most data analysis services, Dolomite Bio will accept sample sizes ranging from as little as one sample, to as many as the research project requires
First launches expected in H1 2022
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Subscribe To Our Newsletter & Stay Updated
